{"transactions":[{"id":4635440,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-03T00:54:14.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":16666,"price":9.4079,"value":156792.0614,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.180 to $9.680, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1111130,"source":{"system":"sec-edgar","filing":"0001867096-26-000084","document":"wk-form4_1790974451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709626000084/wk-form4_1790974451.xml","form_type":"4"}},{"id":670806,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-01T22:21:06.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":16666,"price":8.4864,"value":141434.3424,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.390 to $8.600, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1127796,"source":{"system":"sec-edgar","filing":"0001652410-26-000018","document":"wk-form4_1788301263.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241026000018/wk-form4_1788301263.xml","form_type":"4"}},{"id":696789,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-04T21:16:23.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":16666,"price":8.0135,"value":133552.991,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.870 to $8.140, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1144462,"source":{"system":"sec-edgar","filing":"0001652410-26-000016","document":"wk-form4_1785878178.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241026000016/wk-form4_1785878178.xml","form_type":"4"}},{"id":717140,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-07-02T20:38:57.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":16666,"price":8.0319,"value":133859.6454,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.92 to $8.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,288 shares acquired on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan, as amended."}],"balance_after":1161128,"source":{"system":"sec-edgar","filing":"0001652410-26-000014","document":"wk-form4_1783024734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241026000014/wk-form4_1783024734.xml","form_type":"4"}},{"id":754022,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-06-02T22:05:04.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":16667,"price":6.0588,"value":100982.0196,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.980 to $6.180, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1176506,"source":{"system":"sec-edgar","filing":"0001652410-26-000012","document":"wk-form4_1780437901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241026000012/wk-form4_1780437901.xml","form_type":"4"}},{"id":795259,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-01T21:50:33.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":16667,"price":6.2282,"value":103805.4094,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.100 to $6.320, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1193173,"source":{"system":"sec-edgar","filing":"0001652410-26-000010","document":"wk-form4_1777672230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241026000010/wk-form4_1777672230.xml","form_type":"4"}},{"id":815541,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-04-03T21:45:24.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":16667,"price":5.9914,"value":99858.6638,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.890 to $6.085, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1209840,"source":{"system":"sec-edgar","filing":"0001652410-26-000008","document":"wk-form4_1775252722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241026000008/wk-form4_1775252722.xml","form_type":"4"}},{"id":860633,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-04T22:28:47.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":100,"price":7.06,"value":706.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":1226507,"source":{"system":"sec-edgar","filing":"0001652410-26-000006","document":"wk-form4_1772663325.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241026000006/wk-form4_1772663325.xml","form_type":"4"}},{"id":860632,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-04T22:28:47.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":16567,"price":6.2401,"value":103379.7367,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.920 to $6.910, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1226607,"source":{"system":"sec-edgar","filing":"0001652410-26-000006","document":"wk-form4_1772663325.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241026000006/wk-form4_1772663325.xml","form_type":"4"}},{"id":924480,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-02T23:11:11.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":162162,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date."}],"balance_after":162162,"derivative":{"exercise_price":7.36,"expiration_date":"2036-01-30","underlying":"Common Stock","underlying_shares":162162},"source":{"system":"sec-edgar","filing":"0001652410-26-000004","document":"wk-form4_1770073868.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241026000004/wk-form4_1770073868.xml","form_type":"4"}},{"id":924479,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-02T23:11:11.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":16667,"price":7.4487,"value":124147.4829,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.250 to $7.590, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1243174,"source":{"system":"sec-edgar","filing":"0001652410-26-000004","document":"wk-form4_1770073868.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241026000004/wk-form4_1770073868.xml","form_type":"4"}},{"id":924478,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-02T23:11:11.000Z","date":"2026-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":24266,"price":7.36,"value":178597.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026."}],"balance_after":1259841,"source":{"system":"sec-edgar","filing":"0001652410-26-000004","document":"wk-form4_1770073868.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241026000004/wk-form4_1770073868.xml","form_type":"4"}},{"id":924477,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-02T23:11:11.000Z","date":"2026-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":46914,"price":7.36,"value":345287.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026."}],"balance_after":1284107,"source":{"system":"sec-edgar","filing":"0001652410-26-000004","document":"wk-form4_1770073868.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241026000004/wk-form4_1770073868.xml","form_type":"4"}},{"id":924476,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-02T23:11:11.000Z","date":"2026-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":98375,"price":7.36,"value":724040.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026."}],"balance_after":1331021,"source":{"system":"sec-edgar","filing":"0001652410-26-000004","document":"wk-form4_1770073868.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241026000004/wk-form4_1770073868.xml","form_type":"4"}},{"id":924475,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-02T23:11:11.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":121293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the \"Plan\"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date."}],"balance_after":1429396,"source":{"system":"sec-edgar","filing":"0001652410-26-000004","document":"wk-form4_1770073868.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241026000004/wk-form4_1770073868.xml","form_type":"4"}},{"id":949915,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-01-05T23:01:59.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":16667,"price":7.4264,"value":123775.8088,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.280 to $7.740, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,627 shares acquired on June 30, 2025 and 1,967 shares acquired on December 31, 2025 under the issuer's 2018 Employee Stock Purchase Plan, as amended."}],"balance_after":1308103,"source":{"system":"sec-edgar","filing":"0001652410-26-000002","document":"wk-form4_1767654116.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241026000002/wk-form4_1767654116.xml","form_type":"4"}},{"id":983170,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-02T22:14:20.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":16667,"price":7.0067,"value":116780.6689,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.930 to $7.120, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1320176,"source":{"system":"sec-edgar","filing":"0001652410-25-000005","document":"wk-form4_1764713658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241025000005/wk-form4_1764713658.xml","form_type":"4"}},{"id":999802,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-13T23:59:35.000Z","date":"2025-11-11","kind":"sale","planned":true,"acquired":false,"shares":16667,"price":7.3976,"value":123295.7992,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.290 to $7.750, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1336843,"source":{"system":"sec-edgar","filing":"0001652410-25-000003","document":"wk-form4_1763078372.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000165241025000003/wk-form4_1763078372.xml","form_type":"4"}},{"id":1194410,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-21T21:31:00.000Z","date":"2025-03-20","kind":"sale","planned":false,"acquired":false,"shares":40000,"price":5.4311,"value":217244.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.380 to $5.475, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1353510,"source":{"system":"sec-edgar","filing":"0001867096-25-000047","document":"wk-form4_1742592654.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709625000047/wk-form4_1742592654.xml","form_type":"4"}},{"id":1287033,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Appreciation Right","published_at":"2025-02-04T00:39:53.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock appreciation right granted under the Company's 2018 Stock Option and Incentive Plan will vest in full on the second anniversary of the January 31, 2025 grant date, subject to continued service with the company through the vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Upon exercise, the stock appreciation right will be settled in cash."}],"balance_after":300000,"derivative":{"exercise_price":3.56,"expiration_date":"2027-03-02","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001867096-25-000025","document":"wk-form4_1738629587.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709625000025/wk-form4_1738629587.xml","form_type":"4"}},{"id":1287032,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-04T00:39:53.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years."}],"balance_after":1393510,"source":{"system":"sec-edgar","filing":"0001867096-25-000025","document":"wk-form4_1738629587.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709625000025/wk-form4_1738629587.xml","form_type":"4"}},{"id":1287031,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-04T00:39:53.000Z","date":"2025-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":98375,"price":3.56,"value":350215.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025."}],"balance_after":1208510,"source":{"system":"sec-edgar","filing":"0001867096-25-000025","document":"wk-form4_1738629587.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709625000025/wk-form4_1738629587.xml","form_type":"4"}},{"id":1287030,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-04T00:39:53.000Z","date":"2025-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":45909,"price":3.56,"value":163436.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025."}],"balance_after":1306885,"source":{"system":"sec-edgar","filing":"0001867096-25-000025","document":"wk-form4_1738629587.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709625000025/wk-form4_1738629587.xml","form_type":"4"}},{"id":1307470,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-01-07T21:40:54.000Z","date":"2025-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":32039,"price":3.61,"value":115660.79,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of Restricted Stock Units vested as of January 3, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,031 shares acquired on December 31, 2024 under the Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, as amended."}],"balance_after":1352794,"source":{"system":"sec-edgar","filing":"0001867096-25-000011","document":"wk-form4_1736286048.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709625000011/wk-form4_1736286048.xml","form_type":"4"}},{"id":1436661,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-09T20:07:16.000Z","date":"2024-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":45909,"price":2.46,"value":112936.14,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This transaction is being reported late due to administrative oversight."},{"field":"shares","element":"transactionShares","label":"F10","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2024."}],"balance_after":1380802,"source":{"system":"sec-edgar","filing":"0001867096-24-000170","document":"wk-form4_1723234030.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709624000170/wk-form4_1723234030.xml","form_type":"4"}},{"id":1436660,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-09T20:07:16.000Z","date":"2024-01-29","kind":"tax_withholding","planned":false,"acquired":false,"shares":19675,"price":2.66,"value":52335.5,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This transaction is being reported late due to administrative oversight."},{"field":"shares","element":"transactionShares","label":"F9","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2024."}],"balance_after":1426711,"source":{"system":"sec-edgar","filing":"0001867096-24-000170","document":"wk-form4_1723234030.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709624000170/wk-form4_1723234030.xml","form_type":"4"}},{"id":1436659,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-09T20:07:16.000Z","date":"2024-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":33488,"price":2.24,"value":75013.12,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This transaction is being reported late due to administrative oversight."},{"field":"shares","element":"transactionShares","label":"F8","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2024."}],"balance_after":1446386,"source":{"system":"sec-edgar","filing":"0001867096-24-000170","document":"wk-form4_1723234030.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709624000170/wk-form4_1723234030.xml","form_type":"4"}},{"id":1436658,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-09T20:07:16.000Z","date":"2023-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":5784,"price":1.24,"value":7172.16,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This transaction is being reported late due to administrative oversight."},{"field":"shares","element":"transactionShares","label":"F7","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2023."}],"balance_after":1479874,"source":{"system":"sec-edgar","filing":"0001867096-24-000170","document":"wk-form4_1723234030.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709624000170/wk-form4_1723234030.xml","form_type":"4"}},{"id":1436657,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-09T20:07:16.000Z","date":"2023-01-29","kind":"tax_withholding","planned":false,"acquired":false,"shares":21177,"price":1.26,"value":26683.02,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This transaction is being reported late due to administrative oversight."},{"field":"shares","element":"transactionShares","label":"F6","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2023."}],"balance_after":1485658,"source":{"system":"sec-edgar","filing":"0001867096-24-000170","document":"wk-form4_1723234030.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709624000170/wk-form4_1723234030.xml","form_type":"4"}},{"id":1436656,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-09T20:07:16.000Z","date":"2023-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":33488,"price":1.12,"value":37506.56,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This transaction is being reported late due to administrative oversight."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2023."}],"balance_after":1506835,"source":{"system":"sec-edgar","filing":"0001867096-24-000170","document":"wk-form4_1723234030.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709624000170/wk-form4_1723234030.xml","form_type":"4"}},{"id":1436655,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-09T20:07:16.000Z","date":"2022-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":4448,"price":2.11,"value":9385.28,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This transaction is being reported late due to administrative oversight."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2022."}],"balance_after":1540323,"source":{"system":"sec-edgar","filing":"0001867096-24-000170","document":"wk-form4_1723234030.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709624000170/wk-form4_1723234030.xml","form_type":"4"}},{"id":1436654,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-09T20:07:16.000Z","date":"2022-01-29","kind":"tax_withholding","planned":false,"acquired":false,"shares":14037,"price":2.11,"value":29618.07,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This transaction is being reported late due to administrative oversight."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These shares include 3,840 shares that were purchased on June 30, 2024 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan."}],"balance_after":1544771,"source":{"system":"sec-edgar","filing":"0001867096-24-000170","document":"wk-form4_1723234030.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709624000170/wk-form4_1723234030.xml","form_type":"4"}},{"id":1664802,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-01-31T22:04:44.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares include 7,210 shares that were purchased on June 30, 2023 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan."}],"balance_after":1554968,"source":{"system":"sec-edgar","filing":"0001867096-24-000015","document":"wk-form4_1706738674.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709624000015/wk-form4_1706738674.xml","form_type":"4"}},{"id":1853784,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2023-06-15T21:00:15.000Z","date":"2023-06-15","kind":"exercise","planned":false,"acquired":false,"shares":15853,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted share units (\"RSUs\") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On June 15, 2022, the reporting person was granted an award of 15,853 RSUs, which vested in full on June 15, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On June 15, 2022, the reporting person was granted an award of 15,853 RSUs, which vested in full on June 15, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the \"Reverse Share Split\").  The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":15853},"source":{"system":"sec-edgar","filing":"0001209191-23-037406","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000120919123037406/doc4.xml","form_type":"4"}},{"id":1853783,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-06-15T21:00:15.000Z","date":"2023-06-15","kind":"exercise","planned":false,"acquired":true,"shares":15853,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted share units (\"RSUs\") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the \"Reverse Share Split\").  The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split."}],"balance_after":18839,"source":{"system":"sec-edgar","filing":"0001209191-23-037406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000120919123037406/doc4.xml","form_type":"4"}},{"id":2038218,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-02-01T21:12:19.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares include 5,039 shares that were purchased on June 30, 2022 and 5,898 shares that were purchased on December 31, 2022 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan."}],"balance_after":797758,"source":{"system":"sec-edgar","filing":"0001867096-23-000020","document":"wf-form4_167528592477189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709623000020/wf-form4_167528592477189.xml","form_type":"4"}},{"id":2221747,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2022-06-24T22:00:13.000Z","date":"2022-06-23","kind":"exercise","acquired":false,"shares":36798,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted share units (\"RSUs\") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 23, 2021, the reporting person was granted an award of 36,798 RSUs, which vested on June 23, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 23, 2021, the reporting person was granted an award of 36,798 RSUs, which vested on June 23, 2022."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Ordinary Shares","underlying_shares":36798},"source":{"system":"sec-edgar","filing":"0001209191-22-039311","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000120919122039311/doc4.xml","form_type":"4"}},{"id":2221746,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-06-24T22:00:13.000Z","date":"2022-06-23","kind":"exercise","acquired":true,"shares":36798,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted share units (\"RSUs\") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs."}],"balance_after":44805,"source":{"system":"sec-edgar","filing":"0001209191-22-039311","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000120919122039311/doc4.xml","form_type":"4"}},{"id":2226576,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2022-06-17T21:02:04.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":237795,"price":0.01,"value":2377.95,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit (\"RSU\") represents the contingent right to receive one ordinary share upon vesting of the RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on June 15, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on June 15, 2023."}],"balance_after":237795,"derivative":{"underlying":"Ordinary Shares","underlying_shares":237795},"source":{"system":"sec-edgar","filing":"0001209191-22-037950","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000120919122037950/doc4.xml","form_type":"4"}},{"id":2320782,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2022-03-22T23:00:14.000Z","date":"2022-03-18","kind":"exercise","acquired":false,"shares":7642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted share units (\"RSUs\") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 18, 2021, the reporting person was granted an award of 7,642 RSUs, which vested on March 18, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 18, 2021, the reporting person was granted an award of 7,642 RSUs, which vested on March 18, 2022."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":7642},"source":{"system":"sec-edgar","filing":"0001209191-22-020618","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000120919122020618/doc4.xml","form_type":"4"}},{"id":2320781,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-03-22T23:00:14.000Z","date":"2022-03-18","kind":"exercise","acquired":true,"shares":7642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted share units (\"RSUs\") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs."}],"balance_after":8007,"source":{"system":"sec-edgar","filing":"0001209191-22-020618","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000120919122020618/doc4.xml","form_type":"4"}},{"id":2442716,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-01-05T23:16:41.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares include 3,000 shares that were purchased on June 30, 2021 and 2,455 shares that were purchased on December 31, 2021 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan."}],"balance_after":436821,"source":{"system":"sec-edgar","filing":"0001867096-22-000009","document":"wf-form4_164142458670226.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000186709622000009/wf-form4_164142458670226.xml","form_type":"4"}},{"id":2547878,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:37:19.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"50% of these options vested on the first anniversary of the vesting commencement date, 25% shall vest on the 18-month anniversary of the vesting commencement date and the remaining 25% shall vest on the second anniversary of the vesting commencement date."}],"balance_after":150000,"derivative":{"exercise_price":3.94,"expiration_date":"2030-08-14","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-21-039317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000089924321039317/doc4.xml","form_type":"4"}},{"id":2547877,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:37:19.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":32500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of these options vested on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."}],"balance_after":32500,"derivative":{"exercise_price":13.88,"expiration_date":"2029-01-31","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0000899243-21-039317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000089924321039317/doc4.xml","form_type":"4"}},{"id":2547876,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:37:19.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":3826,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the options vested on October 5, 2019, with the remaining 75% of the shares vesting in 36 equal monthly installments on the fifth day of each month thereafter."}],"balance_after":3826,"derivative":{"exercise_price":19,"expiration_date":"2028-10-04","underlying":"Common Stock","underlying_shares":3826},"source":{"system":"sec-edgar","filing":"0000899243-21-039317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000089924321039317/doc4.xml","form_type":"4"}},{"id":2547875,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:37:19.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":65295,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the options vested on May 15, 2019, with the remaining 75% of the shares vesting in 36 equal monthly installments on the fifteenth day of each month thereafter."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"These options are early exercisable."}],"balance_after":65295,"derivative":{"exercise_price":12.5,"expiration_date":"2028-05-14","underlying":"Common Stock","underlying_shares":65295},"source":{"system":"sec-edgar","filing":"0000899243-21-039317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000089924321039317/doc4.xml","form_type":"4"}},{"id":2547874,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:37:19.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":30879,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the options vested on January 16, 2019, with the remaining 75% of the shares vesting in 36 equal monthly installments on the sixteenth day of each month thereafter."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"These options are early exercisable."}],"balance_after":30879,"derivative":{"exercise_price":5.93,"expiration_date":"2028-01-30","underlying":"Common Stock","underlying_shares":30879},"source":{"system":"sec-edgar","filing":"0000899243-21-039317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000089924321039317/doc4.xml","form_type":"4"}},{"id":2547873,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-05T23:37:19.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":180000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the \"HoldCo RSU\"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the \"Xeris RSU\") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the \"HoldCo RSU\"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the \"Xeris RSU\") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the \"HoldCo RSU\"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the \"Xeris RSU\") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU."}],"balance_after":206366,"source":{"system":"sec-edgar","filing":"0000899243-21-039317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000089924321039317/doc4.xml","form_type":"4"}},{"id":2547872,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-05T23:37:19.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":26366,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Merger Effective Time\"), all existing shares of Xeris common stock (the \"Xeris common stock\") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective Time, net of shares withheld for tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Merger Effective Time\"), all existing shares of Xeris common stock (the \"Xeris common stock\") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective Time, net of shares withheld for tax."}],"balance_after":26366,"source":{"system":"sec-edgar","filing":"0000899243-21-039317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000089924321039317/doc4.xml","form_type":"4"}},{"id":2548331,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T17:34:05.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"50% of these options shall vest on the first anniversary of the vesting commencement date, 25% shall vest on the 18-month anniversary of the vesting commencement date and the remaining 25% shall vest on the second anniversary of the vesting commencement date."}],"balance_after":0,"derivative":{"exercise_price":3.94,"expiration_date":"2030-08-14","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-21-039248","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039248/doc4.xml","form_type":"4"}},{"id":2548330,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T17:34:05.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":32500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."}],"balance_after":0,"derivative":{"exercise_price":13.88,"expiration_date":"2029-01-31","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0000899243-21-039248","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039248/doc4.xml","form_type":"4"}},{"id":2548329,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T17:34:05.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":3826,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the options shall vest on October 5, 2019, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the fifth day of each month thereafter."}],"balance_after":0,"derivative":{"exercise_price":19,"expiration_date":"2028-10-04","underlying":"Common Stock","underlying_shares":3826},"source":{"system":"sec-edgar","filing":"0000899243-21-039248","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039248/doc4.xml","form_type":"4"}},{"id":2548328,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T17:34:05.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":65295,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the options shall vest on May 15, 2019, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the fifteenth day of each month thereafter."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"These options are early exercisable."}],"balance_after":0,"derivative":{"exercise_price":12.5,"expiration_date":"2028-05-14","underlying":"Common Stock","underlying_shares":65295},"source":{"system":"sec-edgar","filing":"0000899243-21-039248","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039248/doc4.xml","form_type":"4"}},{"id":2548327,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T17:34:05.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":30879,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the options shall vest on January 16, 2019, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the sixteenth day of each month thereafter."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"These options are early exercisable."}],"balance_after":0,"derivative":{"exercise_price":5.93,"expiration_date":"2028-01-30","underlying":"Common Stock","underlying_shares":30879},"source":{"system":"sec-edgar","filing":"0000899243-21-039248","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039248/doc4.xml","form_type":"4"}},{"id":2548326,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-05T17:34:05.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":180000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the \"Xeris RSU\"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the \"HoldCo RSU\") on the same terms and conditions  (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the \"Xeris RSU\"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the \"HoldCo RSU\") on the same terms and conditions  (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the \"Xeris RSU\"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the \"HoldCo RSU\") on the same terms and conditions  (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-039248","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039248/doc4.xml","form_type":"4"}},{"id":2548325,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-05T17:34:05.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":26366,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), all existing shares of Xeris common stock (the \"Xeris common stock\") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), all existing shares of Xeris common stock (the \"Xeris common stock\") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax."}],"balance_after":180000,"source":{"system":"sec-edgar","filing":"0000899243-21-039248","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039248/doc4.xml","form_type":"4"}},{"id":2654390,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-25T20:05:21.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":36798,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit (\"RSU\") represents the contingent right to receive one ordinary share upon vesting of the RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on June 23, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on June 23, 2022."}],"balance_after":36798,"derivative":{"underlying":"Ordinary Shares","underlying_shares":36798},"source":{"system":"sec-edgar","filing":"0000899243-21-025952","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000089924321025952/doc4.xml","form_type":"4"}},{"id":2751102,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-12T19:22:04.000Z","date":"2021-04-08","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of AYTU common stock. The RSUs have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below).The RSUs vest as follows, and have no voting or dispositive rights until vested: one year vest from date of grant, April 8, 2021 such that the RSUs will be fully vested on April 8, 2022, subject to the reporting person's continuing employment with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of AYTU common stock. The RSUs have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below).The RSUs vest as follows, and have no voting or dispositive rights until vested: one year vest from date of grant, April 8, 2021 such that the RSUs will be fully vested on April 8, 2022, subject to the reporting person's continuing employment with the Issuer."}],"balance_after":9052,"source":{"system":"sec-edgar","filing":"0001567619-21-007909","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761921007909/doc1.xml","form_type":"4"}},{"id":2777170,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-03-19T20:30:10.000Z","date":"2021-03-18","kind":"grant","acquired":true,"shares":7642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit (\"RSU\") represents the contingent right to receive one ordinary share upon vesting of the RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, the RSUs shall vest on March 18, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, the RSUs shall vest on March 18, 2022."}],"balance_after":7642,"derivative":{"underlying":"Ordinary Shares","underlying_shares":7642},"source":{"system":"sec-edgar","filing":"0000899243-21-012752","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652410/000089924321012752/doc4.xml","form_type":"4"}},{"id":2777546,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T17:34:52.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":46907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":1.44,"underlying":"Common Stock","underlying_shares":46907},"source":{"system":"sec-edgar","filing":"0001104659-21-039226","document":"tm219870-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039226/tm219870-11_4seq1.xml","form_type":"4"}},{"id":2777545,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T17:34:52.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":22756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":6.05,"underlying":"Common Stock","underlying_shares":22756},"source":{"system":"sec-edgar","filing":"0001104659-21-039226","document":"tm219870-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039226/tm219870-11_4seq1.xml","form_type":"4"}},{"id":2777544,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T17:34:52.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":18322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":7.65,"underlying":"Common Stock","underlying_shares":18322},"source":{"system":"sec-edgar","filing":"0001104659-21-039226","document":"tm219870-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039226/tm219870-11_4seq1.xml","form_type":"4"}},{"id":2777543,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T17:34:52.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":14777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":9.63,"underlying":"Common Stock","underlying_shares":14777},"source":{"system":"sec-edgar","filing":"0001104659-21-039226","document":"tm219870-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039226/tm219870-11_4seq1.xml","form_type":"4"}},{"id":2777542,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T17:34:52.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":19.82,"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001104659-21-039226","document":"tm219870-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039226/tm219870-11_4seq1.xml","form_type":"4"}},{"id":2777541,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-19T17:34:52.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":23453,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. (\"Parent\"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") effective as of March 19, 2021 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the \"Exchange Ratio\") shares of Common Stock of Parent (the \"Parent Common Stock\"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement)."},{"field":"shares","element":"transactionShares","label":"F3","text":"This number includes 23,453 restricted stock units (each, an \"RSU\") held by the Reporting Person. At the Effective Time, each RSU that was outstanding prior to the Effective Time immediately and automatically ceased to represent a right to acquire shares of Company Common Stock and was assumed by Parent and converted automatically into a restricted stock unit denominated in Parent Common Stock equal to the number of Shares subject to the RSU prior to the Effective Time multiplied by the Exchange Ratio, and any cash in lieu of fractional shares of Parent Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. (\"Parent\"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") effective as of March 19, 2021 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the \"Exchange Ratio\") shares of Common Stock of Parent (the \"Parent Common Stock\"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-039226","document":"tm219870-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039226/tm219870-11_4seq1.xml","form_type":"4"}},{"id":2888342,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-02-01T16:11:04.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These restricted stock units vest in three substantially equal annual installments beginning on January 29, 2022."}],"balance_after":210814,"source":{"system":"sec-edgar","filing":"0001346302-21-000008","document":"wf-form4_161221385053137.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000134630221000008/wf-form4_161221385053137.xml","form_type":"4"}},{"id":3055574,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-17T16:25:56.000Z","date":"2020-08-14","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of these shares shall vest on the first anniversary of the vesting commencement date, 25% shall vest on the 18-month anniversary of the vesting commencement date and the remaining 25% shall vest on the second anniversary of the vesting commencement date."}],"balance_after":150000,"derivative":{"exercise_price":4.19,"expiration_date":"2030-08-14","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-20-022572","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320022572/doc4.xml","form_type":"4"}},{"id":3082463,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-15T16:54:04.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":3731,"price":2.26,"value":8432.06,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan (\"ESPP\"). It pertains to the ESPP purchase period from January 1, 2020 through June 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2020."}],"balance_after":60814,"source":{"system":"sec-edgar","filing":"0000899243-20-019180","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320019180/doc4.xml","form_type":"4"}},{"id":3113326,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-11T20:22:25.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":23453,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock underlying restricted stock unit grants awarded to the Reporting Person. The restricted stock units will vest on the one-year anniversary of June 10, 2020."}],"balance_after":23453,"source":{"system":"sec-edgar","filing":"0001104659-20-072546","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465920072546/a4.xml","form_type":"4"}},{"id":3208361,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-03-16T16:07:14.000Z","date":"2020-03-13","kind":"purchase","acquired":true,"shares":4000,"price":1.97,"value":7880.0,"ownership":{"direct":true},"balance_after":57083,"source":{"system":"sec-edgar","filing":"0000899243-20-008434","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320008434/doc4.xml","form_type":"4"}},{"id":3237519,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-03-02T16:53:31.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These restricted stock units vest in three substantially equal annual installments beginning on January 31, 2021."}],"balance_after":53083,"source":{"system":"sec-edgar","filing":"0000899243-20-006515","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320006515/doc4.xml","form_type":"4"}},{"id":3266271,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-02-18T17:02:46.000Z","date":"2020-02-14","kind":"purchase","acquired":true,"shares":4000,"price":4.15,"value":16600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares purchased in an underwritten public offering of the Issuer at the public offering price of $4.15 per share."}],"balance_after":8083,"source":{"system":"sec-edgar","filing":"0000899243-20-004913","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320004913/doc4.xml","form_type":"4"}},{"id":3317723,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-01-06T18:17:46.000Z","date":"2019-12-31","kind":"grant","acquired":true,"shares":459,"price":5.99,"value":2749.41,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan (\"ESPP\"). It pertains to the ESPP purchase period from July 1, 2019 through December 31, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on December 31, 2019."}],"balance_after":4083,"source":{"system":"sec-edgar","filing":"0000899243-20-000617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320000617/doc4.xml","form_type":"4"}},{"id":3467532,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2019-07-03T16:58:13.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":1124,"price":9.72,"value":10925.28,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan (\"ESPP\"). It pertains to the ESPP purchase period from January 1, 2019 through June 30, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 28, 2019."}],"balance_after":3928,"source":{"system":"sec-edgar","filing":"0000899243-19-019202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924319019202/doc4.xml","form_type":"4"}},{"id":3487673,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-17T17:33:21.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":46907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in equal quarterly installments over a one-year period which began on June 13, 2019."}],"balance_after":46907,"derivative":{"exercise_price":1.44,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":46907},"source":{"system":"sec-edgar","filing":"0001104659-19-035981","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465919035981/a4.xml","form_type":"4"}},{"id":3638331,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2019-02-22T16:36:01.000Z","date":"2019-02-19","kind":"purchase","acquired":true,"shares":2500,"price":10,"value":25000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Ms. Hecht purchased shares of common stock from the underwriters in a public offering pursuant to the registrant's Registration Statement on Form S-1 (File No. 333-229665, completed on February 19, 2019). The shares of common stock were purchased at the public offering price."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0000899243-19-004561","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924319004561/doc4.xml","form_type":"4"}},{"id":3679405,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-01T16:38:39.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."}],"balance_after":32500,"derivative":{"exercise_price":13.88,"expiration_date":"2029-01-31","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0000899243-19-002322","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924319002322/doc4.xml","form_type":"4"}},{"id":3874917,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-03T16:38:14.000Z","date":"2018-07-02","kind":"grant","acquired":true,"shares":22756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in equal quarterly installments over a one-year period which began on June 20, 2018."}],"balance_after":22756,"derivative":{"exercise_price":6.05,"expiration_date":"2028-07-02","underlying":"Common Stock","underlying_shares":22756},"source":{"system":"sec-edgar","filing":"0001104659-18-043858","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465918043858/a4.xml","form_type":"4"}},{"id":4264257,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-07-05T18:00:55.000Z","date":"2017-07-03","kind":"grant","acquired":true,"shares":18322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in equal quarterly installments over a one-year period which begins on June 15, 2017."}],"balance_after":18322,"derivative":{"exercise_price":7.65,"expiration_date":"2027-07-03","underlying":"Common Stock","underlying_shares":18322},"source":{"system":"sec-edgar","filing":"0001104659-17-043635","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465917043635/a4.xml","form_type":"4"}}]}